Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILDNYSE / NASDAQHealthcareLarge cap

$166.89-$0.68 (-0.4%)

Last close · Data as of Nov 6, 2026

Market cap
$160.4B
P/E
18.8x
EV / EBITDA
12.9x
Revenue
$29.4B
Net margin
28.9%
ROCE
22.7%

+35.2% over the last year

Gilead Sciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools

Open technical chart
Open technical chartCandles, 9 moving averages, RSI, MACD, drawing tools

Performance

Price change over each period, before dividends.

1M
+15.7%
3M
+27.5%
6M
+22.4%
1Y
+35.2%
5Y
+147.3%

52-week range

Day change -$0.68 (-0.4%) from $168 to $167 · Last close Nov 6, 2026

Best weekday to invest, historically

The same weekly amount in GILD, bought on each weekday since 2021.

News & filings

What Gilead Sciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

Strengths1

  • Profit growth of 22.8% CAGR over 3 years

Concerns1

  • Slow revenue growth of 2.6% CAGR over 3 years

Rule-based from financial data. Not advice.

About the company

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.

Read moreShow less

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Sector
Healthcare
Shares outstanding
1.24B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$160.4B
P/E
18.8x
P/B
7.1x
EV / EBITDA
12.9x
EV / Sales
6.0x
P/S
5.4x
52-week high
$174.48
52-week low
$118.15

Profitability

Operating margin
39.7%
Net margin
28.9%
EBITDA margin
46.1%
ROE
37.5%
ROCE
22.7%
ROA
14.4%
Asset turnover
0.50

Growth

Revenue
$29.4B
Revenue growth, 1Y
2.4%
Revenue CAGR, 3Y
2.6%
Net profit growth, 1Y
1672.9%
Free cash flow
$9.5B

Solvency

Current ratio
1.55
Debt / Equity
1.10
Debt / Assets
0.42
CFO / Net profit
1.18
Cash / Market cap
6.0%

Where the revenue went

Of every $100 of FY2025 revenue, $29 was left as net income.

Gilead Sciences, Inc. income statement flow, FY2025
Gilead Sciences, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$6.2B
RevenueGross profit$23.2B
Gross profitResearch and development$5.8B
Gross profitSelling, general and administrative$5.7B
Gross profitOperating income$11.7B
Operating incomePretax income$9.8B
Operating incomeInterest and other expense$1.9B
Pretax incomeTax and other$1.3B
Pretax incomeNet income$8.5B

Revenue and net profit

Revenue grew 2.4% in FY2025; net profit is the dashed line.

Gilead Sciences, Inc. revenue and net profit by fiscal year
Gilead Sciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$27.3B$4.6B
FY2023$27.1B$5.7B
FY2024$28.8B$480.0M
FY2025$29.4B$8.5B

Cash flows

FY2025: $10.0B from operations, $9.5B free after investment (dashed).

Gilead Sciences, Inc. operating and free cash flow by fiscal year
Gilead Sciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$9.1B$8.3B
FY2023$8.0B$7.4B
FY2024$10.8B$10.3B
FY2025$10.0B$9.5B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$29.4B+2.4%1Y
EBITDA
$13.6B+206.3%1Y
Net profit
$8.5B+1,672.9%1Y
Cash from operations
$10.0B-7.5%1Y
Free cash flow
$9.5B-8.2%1Y
Revenue CAGR, 3Y
2.6%
Net profit CAGR, 3Y
22.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$29.4B$13.6B$8.5B$9.5B37.5%+2.4%+1672.9%

Monthly returns

Month-by-month returns of GILD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$59.0B
Liabilities$36.4B
Equity$22.6B
Paid-in capital$8.9B
Retained earnings$13.7B
Minority interest-$84.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GILD highlighted.

P/E against peers

GILD trades at 18.8x earnings against a peer median of 25.5x (a 26% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Gilead Sciences, Inc.GILDthis companyP/E ↓ discount$160.4B18.8x7.1x37.5%12.9x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Peer median—25.5x3.2x12.5%15.9x

Year-to-date ROI

GILD since 1 January, against earlier years.

Historical volatility

GILD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Gilead Sciences, Inc. operating margin by fiscal year
Gilead Sciences, Inc. operating margin by fiscal year
DateOperating margin
FY202240.2%
FY202332.6%
FY202436.9%
FY202539.7%
LineFY2025
Cost of revenueCost Of Revenue$6.2B
Gross profitGross Profit$23.2B
Operating expensesOperating Expense$11.5B
Research and developmentResearch And Development$5.8B
Total expensesTotal Expenses$17.7B
Pretax incomePretax Income$9.8B

Learn while you research

Academy chapters picked for Gilead Sciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →